Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy
Kintor Pharmaceutical Signs Strategic Cooperation Agreement with JD Pharmacy
(Summary description)Kintor Pharmaceutical Limited announced that it has signed a strategic cooperation framework agreement with JD Pharmacy, the pharmaceutical retail channel under JD Health, in a concerted effort to create a patient-centred online innovative healthcare ecosystem. JD Pharmacy will utilise its abundant traffic and resources and strong technological and supply chain capabilities to assist Kintor Pharmaceutical in the marketing and sales of the innovative External use drug KX-826.
- Categories:Company news
- Time of issue:2020-06-28 17:22
Kintor Pharmaceutical Limited (“Kintor Pharmaceutical” or the “Company”, stock code: 9939.HK) announced that it has signed a strategic cooperation framework agreement with JD Pharmacy, the pharmaceutical retail channel under JD Health, in a concerted effort to create a patient-centred online innovative healthcare ecosystem. JD Pharmacy will utilise its abundant traffic and resources and strong technological and supply chain capabilities to assist Kintor Pharmaceutical in the marketing and sales of the innovative External use drug KX-826.
Adhering to the principle of “utilising advantages, mutual facilitation, long-term cooperation, and mutual benefits for win-win”, both parties will move forward with a strategic collaboration, with an aim to jointly create intelligent solutions, a new pharmaceutical ecosystem and a new benchmark for the intelligent services of China’s online pharmacies, as well as to resolve the accessibility problem of innovative drugs, in order to offer patients more convenient and professional solutions.
As China’s largest Pharmaceutical retailer, JD Pharmacy can offer users comprehensive, intelligent and convenient services for drug purchase and use, while providing brands with integrated online marketing solutions to empower the entire pharmaceutical industry chain. Starting with KX-826, this cooperation will achieve the joint strategic expansion of Kintor Pharmaceutical and JD Pharmacy. It is believed that the small step today of signing the collaboration framework agreement will pave the way for deeper cooperation in the future, accumulating capabilities to better benefit patients.
An innovative medicine self-developed by Kintor Pharmaceutical and with applications for approval from the pharmaceutical authorities in both China and the US, KX-826 is an AR antagonist for the treatment of androgenic alopecia and an external targeted drug for designed for local application, which means it can be directly applied to the scalp for targeted therapy. Currently, the drug is in phase II clinical trials in China and phase Ib clinical trials in America. Based on the latest pharmacology research and clinical trials, KX-826 is safe and effective, and it is expected to become a first-in-class AR-targeted new medicine for the treatment of hair loss. As the clinical trials are moving forward quickly and with the strategic collaboration between Kintor Pharmaceutical and JD Pharmacy, KX-826 will redefine the market for hair loss medicines and be available both online and offline, ready for its launch and benefiting more than 100 million alopecia patients in China.
Kintor Pharmaceutical is full of confidence in its cooperation with JD Pharmacy and full of expectations about the comprehensive three-dimensional marketing model involving the new drug. Dr. Tong Youzhi, Executive director and CEO of Kintor Pharmaceutical said: “Kintor Pharmaceutical is excited to kick-start strategic cooperation with China’s largest drug retailer JD Pharmacy. Before the launch of KX-826, Kintor Pharmaceutical has made plans for mobile healthcare and cooperation with JD Pharmacy to develop its online sales channel, empowering its development through the internet. This partnership will help increase the popularity of KX-826 among patients and improve patient education, making advance preparations for Kintor Pharmaceutical to develop its three-dimensional patient education platform. Kintor Pharmaceutical is not only an innovative pharmaceutical company, but also a patient-centred innovative service provider. By simultaneously expanding its online and offline sales channels, it provides patients with what they need to help them fix their actual issues. It also allows patients to enjoy professional services and innovative medicines in the comfort of their home, which makes their life more convenient.”
Jin Enlin, general manager of pharmaceutical division and head of investment at JD Pharmacy, said, “In our partnership with innovative drug company Kintor Pharmaceutical, I believe that we can complement each other’s capabilities and resources to enable patients and JD Pharmacy users access to more innovative drugs, while fully taking advantage of Kintor Pharmaceutical’s strength in professional service, pharma and health retail, in order to develop an online smart drug service ecosystem centring on patients and users, creating a new benchmark for the smart services of online pharmacy in China.”
About Kintor Pharmaceutical Limited
Founded in 2009, Kintor Pharmaceuticals concentrates on the R&D and industrialisation of “best-in-class” and “first-in-class” innovative drugs, and strives to become a leading enterprise in the R&D and commercialization of innovative therapies. The Company, after years of development, centered upon androgen receptor (AR) related diseases and researched and developed product portfolios in multiple channels covering cancers with a globally high incidence and illnesses yet to meet their clinical requirements, such as prostate cancer, breast cancer, liver cancer and hair loss. Kintor Pharmaceuticals has prospectively deployed a diversified product pipeline that includes small molecule innovative drugs, bioinnovative drugs and combination therapies, including 5 products that are undergoing clinically researched androgen receptor antagonists, ALK-1 monoclonal antibody, mTOR kinase inhibitors and Hedgehog inhibitors, as well as AR-Degrader, c-Myc inhibitors and IDO inhibitors that are undergoing preclinical research. Globally, the Company owns more than 60 patents, many of which are listed as the “Major New Drugs Discovery” in National 12th and 13th Five-Year Plans. On 22 May 2020, the Company was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK.
About JD Pharmacy
The pharmaceutical retail business under JD Health, JD Pharmacy is the largest drug retailer selling drugs from the highest number of brands in China. In China, JD Pharmacy has seven warehouses, located in the core cities of the country’s north, east, south, southeast, northwest and northeast, each of which covers a large region, enabling 50% delivery on the next day and 80% delivery on the following day. Since its founding in 2017, JD Pharmacy has centred upon “medical and pharmaceutical linkage” and created the whole industry’s first “healthcare + drugs” closed loop, bringing consumers comprehensive, intelligent, convenient and professional medicine purchase experience and drug use services. Meanwhile, with the big data and resource strengths of its parent company JD.com, JD Pharmacy can provide brands with integrated online marketing solutions and its industry peers with integrated values, thus empowering the drug industry chain. To date, JD Pharmacy has achieved online and offline integrated drug omni-channel coverage, comprehensively serving the scenarios of serious, urgent and chronic conditions. It pioneered the professional service, drug and health retail model, in which it is committed to cooperating with partners and jointly create the most trustworthy and professional supply and service system, so as to continuously enhance drug accessibility and patient compliance.